- About Us
- Advertise
- Contact Us
- CureToday.com
- CancerNetwork.com
- OncLive.com
- OncNursingNews.com
- Do Not Sell My Information
- Privacy
- Terms & Conditions
© 2022 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Latest Oncology News
Polatuzumab Shows Improved Survival and Complete Responses in R/R DLBCL
July 06, 2022
Ian W. Flinn, MD, PhD, discusses the study design and results of the phase 2 trial of the antibody-drug conjugate polatuzumab vedotin-piiq plus bendamustine and rituximab for patients with relapsed/refractory diffuse large B-cell lymphoma.
Durvalumab Added to Standard Chemotherapy Prolongs OS in Advanced Biliary Tract Cancer
July 06, 2022
In the phase 3 TOPAZ-1 trial, the addition of durvalumab to standard-of-care chemotherapy achieved a statistically significant improvement in overall survival compared chemotherapy alone, meeting the study's primary end point.
FDA Grants Priority Review to Mosunetuzumab for Relapsed/Refractory Follicular Lymphoma
July 06, 2022
The FDA has granted priority review to an approval application for mosunetuzumab for the treatment of patients with relapsed or refractory follicular lymphoma.
FDA Grants RPDD to Paxalisib for Rare Pediatric Brain Cancer
July 06, 2022
Rare pediatric disease designation has been awarded to paxalisib for the treatment of patients with atypical rhabdoid or teratoid tumors in rare and highly-aggressive childhood brain cancer.
Bishop Reviews Risk Assessment and Treatment for GVHD
July 06, 2022
Michael R. Bishop, MD, discussed a patient with graft-versus-host disease who first underwent a myeloablative conditioning regimen and peripheral blood stem-cell matched hematopoietic cell transplant as treatment.
Emerging Treatment Approaches in HER2+ Breast Cancer
July 06, 2022
Before closing out their discussion on HER2+ breast cancer, expert oncologists share excitement for emerging treatment strategies and ongoing clinical trials.
Roundtable Discussion: Wagner-Johnson Highlights New and Emerging Approaches for DLBCL
July 06, 2022
Experts discuss the newest approaches for treating patients with diffuse large B-cell lymphoma.
Selumetinib and RAI Fails to Achieve Significant CR in Differentiated Thyroid Cancer
July 05, 2022
Data from the phase 3 ASTRA study show that selumetinib does not induce a complete remission in patients with differentiated thyroid cancer.
VISION Trial Shows Survival Benefit of Lutetium Radioligand for mCRPC
July 05, 2022
During a live virtual event, Emmanuel S. Antonarakis, MD, discussed the VISION trial supporting the use of 177-lutetium-PSMA-617 for patients with metastatic castration-resistant prostate cancer. This is the second of 2 articles from this event.
Traina Discusses Components of the ASCENT Trial in Patients With TNBC
July 05, 2022
Tiffany A. Traina, MD, discussed the ASCENT Trial examining patients with triple negative breast cancer.
Roundtable Discussion: Stinchcombe Reviews Second-Line Therapy for ES-SCLC
July 05, 2022
During a Targeted Oncology case-based roundtable event Thomas E. Stinchcombe, MD, discussed the case of a 53-year-old patient with extensive-stage small cell lung cancer.
Frontline Treatment Approaches to Nonmetastatic CRPC
July 04, 2022
Returning to the patient case, experts review available frontline treatment options in the setting of nonmetastatic castration-resistant prostate cancer.